U.S. Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel

Description

List of Tables

The U.S. gout therapeutics market size is expected to reach USD 2.73 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. gout therapeutics market focuses on the development, distribution, and adoption of pharmaceutical solutions aimed at managing uric acid buildup and the associated inflammation that causes acute and chronic gout. The market is expanding due to the rising incidence of comorbid conditions such as obesity, hypertension, and metabolic syndrome, all of which increase gout risk. Demand is further strengthened by heightened awareness among both patients and providers regarding early diagnosis and sustained treatment. Strong reimbursement frameworks and access to specialty care support the uptake of biologics and next-generation urate-lowering agents. Market participants are actively investing in therapies that offer better tolerability, lower dosing frequency, and reduced cardiovascular risks. Industry trends point to a shift toward personalized care, emphasizing biomarkers and patient-specific therapeutic responses.

The integration of digital health platforms into gout management is creating new channels for monitoring and adherence. Opportunities exist in expanding treatment access to underserved populations, improving disease education, and addressing medication non-compliance. Innovation in drug formulation, including oral biologics and dual-action therapies, is driving product differentiation. The increasing willingness among payers to reimburse high-cost but high-efficacy treatments reflects the demand for long-term cost containment through effective disease control. Clinical focus is shifting beyond flare reduction to long-term prevention and comorbidity management, positioning the market for continued innovation. Expansion into combination therapies, supported by strong post-market surveillance data, is expected to shape the future landscape. The market is aligning around outcomes-based value, driving both clinical and economic incentives for continued investment.

U.S. Gout Therapeutics Market Report Highlights

By drug class, the NSAIDs segment dominated the U.S. gout therapeutics market with ~43% of the revenue share in 2024 due to their rapid action in reducing inflammation and pain associated with acute gout flares

Based on disease condition, the chronic gout segment held the largest revenue share in 2024 due to growing demand for long-term management therapies.

A few key players include Arrowhead Pharmaceuticals, Inc.; AstraZeneca; GSK plc.; Eisai Co., Ltd.; Merck & Co., Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teijin Pharma Ltd.; and Zydus Group.

Polaris Market Research has segmented the market report on the basis of disease condition, drug class, and distribution channel:

By Disease Condition Outlook (Revenue, USD Billion, 2020-2034)

Acute Gout

Chronic Gout

By Drug Class Outlook (Revenue, USD Billion, 2020-2034)

NSAIDs

Corticosteroids

Colchicine

Urate-Lowering Agents

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Product Code: PM6279

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. U.S. Gout Therapeutics Market Insights

4.1. Gout Therapeutics Market - Market Snapshot
4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Obesity and Metabolic Syndrome Prevalence
  - 4.2.1.2. Strong Commercial and Insurance Coverage
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High drug pricing and payer restrictions limit patient access and slow adoption of newer, more effective gout treatments across insurance plans.
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Gout Therapeutics Market Trends
4.6. Value Chain Analysis

5. U.S. Gout Therapeutics Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
5.3. NSAIDs
- 5.3.1. U.S. Gout Therapeutics Market, by NSAIDs, 2020-2034 (USD Billion)
5.4. Corticosteroids
- 5.4.1. U.S. Gout Therapeutics Market, by Corticosteroids, 2020-2034 (USD Billion)
5.5. Colchicine
- 5.5.1. U.S. Gout Therapeutics Market, by Colchicine, 2020-2034 (USD Billion)
5.6. Urate-Lowering Agents
- 5.6.1. U.S. Gout Therapeutics Market, by Urate-Lowering Agents, 2020-2034 (USD Billion)
5.7. Others
- 5.7.1. U.S. Gout Therapeutics Market, by Others, 2020-2034 (USD Billion)

6. U.S. Gout Therapeutics Market, by Disease Condition

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
6.3. Acute Gout
- 6.3.1. U.S. Gout Therapeutics Market, by Acute Gout, 2020-2034 (USD Billion)
6.4. Chronic Gout
- 6.4.1. U.S. Gout Therapeutics Market, by Chronic Gout, 2020-2034 (USD Billion)

7. U.S. Gout Therapeutics Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacy
- 7.3.1. U.S. Gout Therapeutics Market, by Hospital Pharmacy, 2020-2034 (USD Billion)
7.4. Retail Pharmacy
- 7.4.1. U.S. Gout Therapeutics Market, by Retail Pharmacy, 2020-2034 (USD Billion)
7.5. Online Pharmacy
- 7.5.1. U.S. Gout Therapeutics Market, by Online Pharmacy, 2020-2034 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Arrowhead Pharmaceuticals, Inc.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. AstraZeneca
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Eisai Co., Ltd.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. GSK plc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Merck & Co., Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Novartis AG
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Takeda Pharmaceutical Company Limited
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Teijin Pharma Ltd.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Zydus Group
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Regeneron Pharmaceuticals Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development